Cambridge, Massachusetts-based Editas Medicine, a clinical-stage biotechnology company developing therapies for rare diseases using CRISPR gene editing technology. has announced a 65% reduction of its workforce as a “critical pivot to optimize its cost structure.
A Cambridge-based biotechnology company announced Thursday its plans to lay off about 65% of its workforce over the next several months.
The reduction will impact 180 employees and follow a previous restructuring in 2023. The Company expects to substantially complete the Reduction by the end of June 2025.
According to President and Chief Executive Officer Gilmore O’Neill, “Two years ago, we laid out our strategy and objective to become a leader in in vivo programmable gene editing. Based on these advances, we are transitioning to a fully in vivo company."
"We want to extend our deepest appreciation to patients, investigators, clinical sites staff, and our employees who have shown tremendous dedication and commitment to developing a potentially transformational medicine like reni-cel. We also want to express specific gratitude to the patients in our clinical trials and their caregivers whose dedication to disease research for their community makes us even more committed to accelerating our efforts towards an in vivo program for sickle cell disease and beta thalassemia.”
Change is coming. There will always be a tomorrow, no matter how much you may try to ignore it. There are no guarantees in life or promises for a bright future. We see good people being laid off through no fault of their own. Just because something terrible hasn't happened yet doesn't mean it won't. It can happen to anyone, anytime, anywhere. No one is guaranteed to wake up tomorrow and still have a job by evening. While many employees can read the writing on the wall, why do most assume it’s targeted at someone else? Are you now wondering, Am I Next?